JPM and Havel, Holasek & Parters have advised Dr. Max Group on the acquisition by its AsterFarm subsidiary of prominent Serbian pharmacy chains Farmanea and Farmakop. Bojanovic & Partners advised the sellers, Lovorka Nikolic and Miomir Nikolic.
Dr. Max Group is a group member of Penta Investment Group, the largest pharmacy network in Central and Eastern Europe. According to JPM, "Dr. Max is one of the biggest pharmacy chains in the CEE, the market leader in Czechia and Slovakia, and one of the biggest pharmacy chains in Poland. It operates almost 1000 pharmacies and serves more than 210,000 customers daily."
JPM also advised Dr. Max Group throughout the merger control procedure before the Serbian competition authority regarding its acquisition of sole control over Farmanea and Farmakop, which resulted in the Commission for Protection of Competition's unconditional approval.
Partners Jelena Stankovic and Nikola Poznanovic led JPM team's, with Partner Nikola Poznanovic representing Dr. Max Group during merger approval procedures before the Commission for Protection of Competition.
The Havel, Holasek & Partners team was led by Partner Vaclav Audes, supported by Jan Frey (who has since moved from Managing Associate to Partner) and Associate Martin Strban.
The Bojanovic & Partners team was led by Partner Vladimir Bojanovic and Senior Associate Stefan Jovicic.